Solcitinib( GSK-2586184 | GLPG-0778 )

Catalog No. M10753 CAS No. 1206163-45-2

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Solcitinib
Note

Research use only, not for human use.
Brief Description

A potent, selective JAK1 inhibitor for the treatment of psoriasis, lupus, and ulcerative colitis.
Description

A potent, selective JAK1 inhibitor for the treatment of psoriasis, lupus, and ulcerative colitis.Psoriasis Phase 2 Clinical(In Vitro):Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
In Vitro

Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
In Vivo

——
Synonyms

GSK-2586184 | GLPG-0778
Pathway

Angiogenesis
Target

JAK
Recptor

JAK1
Research Area

Inflammation/Immunology
Indication

Psoriasis

CAS Number

1206163-45-2
Formula Weight

389.4503
Molecular Formula

C22H23N5O2
Purity

>98% (HPLC)
Solubility

DMSO: 20 mg/mL
SMILES

CC1(CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(=NN43)NC(=O)C5CC5)C
Chemical Name

Cyclopropanecarboxamide, N-[5-[4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-